Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Genzyme and Isis Say Cholesterol Drug Met Goal

By Pharmaceutical Processing | May 20, 2009

NEW YORK (AP) — Genzyme Corp. and Isis Pharmaceuticals Inc. on Wednesday reported successful trial results for mipomersen, as the companies said the cholesterol drug candidate met its primary goal in late stage clinical testing. Mipomersen reduced patients’ levels of LDL cholesterol, also called bad cholesterol, by 25 percent after six months, the companies said. Patients who received a dummy injection experienced a reduction of 3 percent. Genzyme, which is based in Cambridge, Mass., plans to ask the Food and Drug Administration for marketing approval late next year. That is about a year later than originally planned. The companies suffered a setback in early 2008, when regulators said they wanted to see preclinical study data before reviewing the application. The preclinical studies test whether mipomersen caused cancer. Those tests are still being conducted. In the trial, patients were injected with either 200 mg of mipomersen or a placebo once a week for 26 weeks. The patients have a condition called homozygous familial hypercholesterolemia, a genetic disorder that prevents them from properly metabolizing LDL cholesterol. Of the 34 patients treated with mipomersen, 28 finished the drug. The companies said one patient stopped because of elevated levels of a type of liver enzyme called transaminases. Other common side effects included reactions at the site of injection and flu-like symptoms. Full results from the trial will be presented at a future medical conference. Isis, which is based in Carlsbad, Calif., discovered the drug, and licensed it to Genzyme in January 2008.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE